Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, Skuljec J, Revie L, Giglhuber K, Häußler V, Karenfort M, Hellwig K, Paul F, Bellmann-Strobl J, Otto C, Ruprecht K, Ziemssen T, Emmer A, Rothhammer V, Nickel FT, Angstwurm K, Linker R, Laurent SA, Warnke C, Jarius S, Korporal-Kuhnke M, Wildemann B, Wolff S, Seipelt M, Yalachkov Y, Retzlaff N, Zettl UK, Rommer PS, Kowarik MC, Wickel J, Geis C, Hümmert MW, Trebst C, Senel M, Gold R, Klotz L, Kleinschnitz C, Meuth SG, Aktas O, Berthele A, Ayzenberg I; German Neuromyelitis Optica Study Group (NEMOS).
Ringelstein M, et al.
Neurology. 2024 Nov 12;103(9):e209888. doi: 10.1212/WNL.0000000000209888. Epub 2024 Oct 1.
Neurology. 2024.
PMID: 39353149
Free PMC article.
METHODS: We retrospectively evaluated patients with AQP4-IgG+ NMOSD treated with ECU between December 2014 and April 2022 at 20 German and 1 Austrian university center(s) of the Neuromyelitis Optica Study Group (NEMOS) by chart review. Primary outcomes were effectiveness ( …
METHODS: We retrospectively evaluated patients with AQP4-IgG+ NMOSD treated with ECU between December 2014 and April 2022 at 20 German and 1 …